| Name | Title | Contact Details |
|---|
Gene Link Inc is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Signum Biosciences Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.